Works matching Jonsson Comprehensive Cancer Center (JCCC)


Results: 29
    1
    2

    Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.

    Published in:
    Neuro-Oncology Advances, 2023, v. 5, n. 1, p. 1, doi. 10.1093/noajnl/vdad041
    By:
    • Jordan, Justin T;
    • Orr, Christina C;
    • Thalheimer, Raquel D;
    • Cambillo, Josephine V;
    • Beauchamp, Roberta L;
    • Shaikh, Ghalib;
    • Muzikansky, Alona;
    • Stemmer-Rachamimov, Anat;
    • Giovannini, Marco;
    • Kalamarides, Michel;
    • Barker, Fred G;
    • Ramesh, Vijaya;
    • Plotkin, Scott R
    Publication type:
    Article
    3
    4
    5

    Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

    Published in:
    Communications Biology, 2018, v. 1, n. 1, p. N.PAG, doi. 10.1038/s42003-018-0163-y
    By:
    • Isakson, Sara H.;
    • Rizzardi, Anthony E.;
    • Coutts, Alexander W.;
    • Carlson, Daniel F.;
    • Kirstein, Mark N.;
    • Fisher, James;
    • Vitte, Jeremie;
    • Williams, Kyle B.;
    • Pluhar, G. Elizabeth;
    • Dahiya, Sonika;
    • Widemann, Brigitte C.;
    • Dombi, Eva;
    • Rizvi, Tilat;
    • Ratner, Nancy;
    • Messiaen, Ludwine;
    • Stemmer-Rachamimov, Anat O.;
    • Fahrenkrug, Scott C.;
    • Gutmann, David H.;
    • Giovannini, Marco;
    • Moertel, Christopher L.
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13

    Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.

    Published in:
    International Journal of Cancer, 2020, v. 147, n. 9, p. 2564, doi. 10.1002/ijc.33144
    By:
    • Ma, Junzhi;
    • Klemm, Janina;
    • Gerardo‐Ramírez, Monserrat;
    • Frappart, Lucien;
    • Castven, Darko;
    • Becker, Diana;
    • Zoch, Ansgar;
    • Parent, Romain;
    • Bartosch, Birke;
    • Minnich, Kerstin;
    • Giovannini, Marco;
    • Danckwardt, Sven;
    • Hartmann, Nils;
    • Morrison, Helen;
    • Herrlich, Peter;
    • Marquardt, Jens U.;
    • Hartmann, Monika
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20

    Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

    Published in:
    Nature Communications, 2014, v. 5, n. 12, p. 5712, doi. 10.1038/ncomms6712
    By:
    • Müller, Judith;
    • Krijgsman, Oscar;
    • Tsoi, Jennifer;
    • Robert, Lidia;
    • Hugo, Willy;
    • Song, Chunying;
    • Kong, Xiangju;
    • Possik, Patricia A.;
    • Cornelissen-Steijger, Paulien D. M.;
    • Foppen, Marnix H Geukes;
    • Kemper, Kristel;
    • Goding, Colin R.;
    • McDermott, Ultan;
    • Blank, Christian;
    • Haanen, John;
    • Graeber, Thomas G.;
    • Ribas, Antoni;
    • Lo, Roger S.;
    • Peeper, Daniel S.
    Publication type:
    Article
    21

    Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.

    Published in:
    NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00561-y
    By:
    • Turner, Nicholas C.;
    • Laird, A. Douglas;
    • Telli, Melinda L.;
    • Rugo, Hope S.;
    • Mailliez, Audrey;
    • Ettl, Johannes;
    • Grischke, Eva-Maria;
    • Mina, Lida A.;
    • Balmaña, Judith;
    • Fasching, Peter A.;
    • Hurvitz, Sara A.;
    • Hopkins, Julia F.;
    • Albacker, Lee A.;
    • Chelliserry, Jijumon;
    • Chen, Ying;
    • Conte, Umberto;
    • Wardley, Andrew M.;
    • Robson, Mark E.
    Publication type:
    Article
    22
    23
    24

    Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.

    Published in:
    Nature Communications, 2023, p. 1, doi. 10.1038/s41467-023-37226-0
    By:
    • Chiasson-MacKenzie, Christine;
    • Vitte, Jeremie;
    • Liu, Ching-Hui;
    • Wright, Emily A.;
    • Flynn, Elizabeth A.;
    • Stott, Shannon L.;
    • Giovannini, Marco;
    • McClatchey, Andrea I.
    Publication type:
    Article
    25
    26
    27
    28
    29